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PODIUM SESSION II: MIXED TREATMENT COMPARISON 
METHODOLOGY AND APPLICATIONS
MT1
DOES MODEL CHOICE IN MIXED TREATMENT COMPARISONS AFFECT 
THE OUTCOME FOR DECISION-MAKERS?
Adams RC1, Schmitz S2, Fitzgerald O3, Walsh C2, Barry M1
1National Centre for Pharmacoeconomics, Dublin, Ireland; 2Trinity College Dublin, Dublin, 
Ireland; 3St. Vincents University Hospital, Dublin Academic Healthcare, Dublin, Ireland
BACKGROUND: An incremental cost-effectiveness ratio is calculated by dividing the 
difference in cost of an intervention by the difference in effect. In the absence of head 
to head trials, it is often necessary to combine evidence from placebo-controlled trials 
of different treatments and thereby derive an estimate of effect of one treatment against 
another. There are formal methods to do this and various models can be used. We 
present four different models and examine whether using different models can change 
the conclusion of the economic evaluation in rheumatoid arthritis (RA). METHODS: 
A literature review was carried out and the relevant data were extracted according to 
deﬁ ned inclusion criteria. The outcome measures chosen were American College of 
rheumatology (ACR) 20 and 50 at 6 months. The MTC was carried out in WinBUGS 
and the method used was that by Nixon et al.[1]. This model allows inclusion of 
methotrexate as a parameter. We then used the four different estimates from each of 
the models in an RA model. RESULTS: The four different models differed in whether 
random or ﬁ xed effect was applied to the treatment or to methotrexate. Pairwise risk 
ratios (RR) are presented. The RR differ slightly for the same drug using the different 
models. Both the positioning of the ICERs on the CE plane and the probability of 
cost-effectiveness change from model to model. CONCLUSIONS: We see a difference 
in the results of using different models for MTC. However, the relative positioning of 
the estimates remains the same. Therefore, in deciding which method to choose in the 
case of biological agents, it is unlikely that the choice of model will impact greatly on 
the overall decision.
MT2
CONDUCTING A MIXED TREATMENT COMPARISON (MTC) IN A 
SPECIFIC POPULATION: POSTMENOPAUSAL WOMEN WITH 
METASTATIC HORMONE RECEPTOR POSITIVE BREAST CANCER 
WHICH OVEREXPRESSES HER2
Pacou M1, Gauthier A1, Abrams K2, Moore L3, Jiang Y1, McNamara S3
1Amaris Consulting UK, London, UK; 2University of Leicester, Leicester, UK; 3Roche Products 
Limited, Welwyn Garden City, UK
OBJECTIVES: To estimate the relative treatment effects on progression free survival 
(PFS) and overall survival (OS) of trastuzumab plus an aromatase inhibitor (AI), lapa-
tinib plus an AI, and AI monotherapy (anastrozole, letrozole, or exemestane) in 
postmenopausal women with untreated metastatic hormone receptor positive breast 
cancer which overexpresses HER2. METHODS: A systematic literature review was 
conducted in MEDLINE, MEDLINE-IN-PROCESS, EMBASE, Cochrane CENTRAL, 
Web of Science Proceedings, and BIOSIS to retrieve relevant randomized clinical trials. 
Heterogeneity and inconsistency were discussed with clinical experts and assessed 
statistically. An MTC was developed within the Bayesian framework using noninfor-
mative priors. It was decided a priori to investigate whether AIs could be considered 
as a class, through the evaluation of hazard ratios between single agents. As few trials 
focused on the exact target population, extensive sensitivity analyses were planned. 
RESULTS: The base-case analysis indicated no signiﬁ cant difference between AIs on 
PFS. Combined therapies were signiﬁ cantly more effective than AIs: the hazard ratios 
were estimated at 0.55 (95% CrI: [0.41; 0.74]) for trastuzumab + AI and 0.71 (95% 
CrI: [0.53; 0.96]) for lapatinib + AI. Although the probability of being best varied in 
the sensitivity analyses, trastuzumab + AI was always associated with the highest 
probability of best efﬁ cacy. The effect on OS was similar across AIs. No signiﬁ cant 
difference was found between the two combination therapies, which were associated 
with high probabilities of best efﬁ cacy (48% for trastuzumab + AI and 50% for lapa-
tinib + AI). The sensitivity analyses indicated that adjustment for cross-over had an 
important impact on the OS results. CONCLUSIONS: Our study conﬁ rmed that 
anastrozole, letrozole, and exemestane had similar efﬁ cacy with respect to PFS and 
OS and that combined therapies were associated with signiﬁ cantly improved PFS 
compared to AIs. Conducting an MTC in this speciﬁ c population was addressed 
through clinical and statistical assessments of heterogeneity and inconsistency, and 
extensive sensitivity analyses.
MT3
COMPARATIVE EFFECTIVENESS OF ANTIDEPRESSANTS (AD) IN THE 
TREATMENT OF THE ELDERLY WITH MAJOR DEPRESSIVE DISORDER 
(MDD): A MIXED TREATMENT COMPARISON AND META-REGRESSION 
ANALYSIS
Benedict A1, Naci H2, Fahrbach K3, Bozkaya D3, Happich M4, Deberdt W5, Raskin J6
1United BioSource Corporation, Budapest, Hungary; 2United BioSource Corporation, 
London, UK; 3United BioSource Corporation, Lexington, MA, USA; 4Eli Lilly & Company, 
Bad Homburg, Hessia, Germany; 5S.A. Eli Lilly Benelux N.V., Bruxelles, Belgium; 6Eli Lilly & 
Company, Toronto, ON, Canada
OBJECTIVES: To estimate the probability of clinical response, remission, and treat-
ment withdrawal of antidepressants including TCAs, SSRIs, mirtazapine, buproprion, 
and SNRIs in elderly patients with MDD using indirect comparison (MTC) and meta-
regression (MR) methods. METHODS: Published systematic reviews of AD in elderly 
patients with MDD were used to extract data from RCTs of comparator treatments 
reporting response or remission or treatment withdrawal. Studies with less than 6 
weeks duration, open label extension studies, and studies in patients with signiﬁ cant 
dementia were excluded. Bayesian MTC and MR analyses, enabling indirect compari-
sons of interventions while respecting randomization, were performed using OpenBugs 
3.0.2, adjusting for placebo control, baseline disease severity, treatment duration, age, 
patients with late onset depression as study, or arm level covariates as appropriate. 
Assuming similar class efﬁ cacy TCAs and SSRIs were grouped. RESULTS: The ﬁ nal 
data set included 40 studies, with 87 comparator arms. Placebo control was associated 
with a reduction in the log odds ratio (LOR) of response versus placebo for all treat-
ments. Severity and publication year was marginally correlated with response. Poste-
rior median predicted response and remission rates in non-placebo-controlled studies 
ranged between 71.9% (buproprione) and 77.1% (duloxetine), and remission between 
29.4% (SSRIs), 42.7% (duloxetine), and 58.1% (TCAs). Predicted withdrawal rates 
for non-placebo-controlled studies vary between 25.7% (duloxetine) and 40% (ven-
lafaxine). Remission results were sensitive to how the mean placebo incidence across 
studies was modeled. CONCLUSIONS: In the absence of head-to-head clinical trials, 
this analysis provides comparative estimates of relative treatment effect of AD among 
elderly with MDD while statistically taking into account heterogeneity. Although 
statistically not different, results suggest that among the elderly, duloxetine and TCAs 
produce the largest clinical response and remission rates, with relatively favorable 
withdrawal rates for duloxetine.
MT4
MIXED TREATMENT COMPARISON (MTC) OF ANTIFUNGAL DRUGS 
FOR PROPHYLAXIS TREATMENT AGAINST INVASIVE FUNGAL 
INFECTIONS (IFIS) IN PATIENTS RECEIVING CHEMOTHERAPY FOR 
HEMATOLOGICAL MALIGNANCIES OR ALLOGENEIC HEMATOPOIETIC 
STEM CELLS TRANSPLANTATION
Pechlivanoglou P, Le HH, De Vries R, Postma MJ
University of Groningen, Groningen, The Netherlands
OBJECTIVES: Neutropenic patients treated with chemotherapy for hematological 
malignancies and recipients of allogeneic hematopoietic stem cells transplantation 
(HSCT) are at high risk of acquiring invasive fungal infections (IFIs). Prognoses for 
IFIs are poor in terms of mortality and morbidity. An important factor in improving 
outcome is early treatment with antifungal agents. Early treatment, however, is com-
plicated by a number of factors, including poor diagnostic measures. As a conse-
quence, antifungal prophylaxis may be an effective strategy. Use of antifungal 
prophylaxis remains a matter of controversy, without a clear consensus on the choice 
of drug treatment. In this study, we used mixed treatment comparison (MTC) meth-
odologies to compare the effectiveness of different antifungal drugs used in prophy-
laxis treatments against IFIs in high-risk patients. METHODS: Through systematic 
and transparent methodologies, MTC techniques allow for the combination of evi-
dences from different sources and as a result may provide information where none 
exists or where direct comparisons are incomplete. For the estimation of effectiveness, 
we collected evidence on proven or probable IFIs from 13 different randomized clinical 
trials (RCTs). Comparisons of interest included placebo, ﬂ uconazole, itraconazole, 
voriconazole, and micafungin. The MTC analyses were carried out through the appli-
cation of Bayesian hierarchical models. RESULTS: Signiﬁ cant evidence was found on 
the superiority of all study drugs versus placebo for preventing IFIs. Furthermore, 
MTC analyses indicated that the probability of acquiring an IFI after voriconzole 
prophylaxis is signiﬁ cantly lower than after ﬂ uconazole prophylaxis (dOR = 0,17 95% 
CI = [0.03, 0.94]). Comparisons between all other antifungals yielded no signiﬁ cant 
differences in incidence of IFIs. CONCLUSIONS: After the application of MTC 
methodologies on RCT evidence, the authors found evidence suggesting that prophy-
laxis with antifungals is superior to placebo and prophylaxis with voriconazole is 
superior to ﬂ uconazole regarding reduction in incidence of IFIs. 
PODIUM SESSION II: DEVELOPMENTS IN HTA AGENCIES LIKE NICE
NI1
RETROSPECTIVE ANALYSIS OF TECHNOLOGY APPRAISALS 
CONDUCTED BY UK’S NATIONAL INSTITUTE FOR HEALTH AND 
CLINICAL EXCELLENCE (NICE) IN SEVERAL CANCER INDICATIONS: 
HIGHER EVIDENCE BARRIERS FOR TARGETED THERAPIES?
Banerji L, Das S
J&D Associates, London, London, UK
OBJECTIVES: We undertook a retrospective analysis of NICE technology appraisals 
in NSCLC, hematological malignancies, gastric and breast cancer, and compared 
submission evidence with ﬁ nal NICE recommendation. METHODS: The analysis was 
based on a review of published appraisals on the NICE website from 2007 to 2010. 
RESULTS: Over the past 3 years, NICE completed 15 appraisals in the indications of 
NSCLC, hematological malignancies, and gastric and breast cancer. Ten of these 
appraisals were of targeted therapies. A total of ﬁ ve out of 15 appraisals were not 
recommended mainly because of weak clinical evidence surrounding efﬁ cacy. One of 
these technologies, Lapatinib, was not recommended for breast cancer despite the 
manufacturer offering a patient-access scheme. Focusing on the 10 appraisals that 
received positive recommendation, four appraisals received unconditional reimburse-
ment. Rituximab is the only targeted therapy to receive unconditional reimbursement 
because it was cost-effective (<£30, 000 per QALY) due to the strong clinical evidence 
that demonstrated PFS >10 months compared to chemotherapy in CLL. The remaining 
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six assessments that resulted in conditional reimbursement were targeted therapies. 
Typically, with these targeted therapies, PFS or OS ranged from ~3 months to 9 
months with the cost-per-QALY > £45.000. Five of the six manufactures participated 
in a patient-access scheme which consisted of ﬁ xed-price discounts such as Cetuximab 
(CRC) and Geﬁ tinib (NSCLC) or performance schemes like sunitinib (GIST), Bortezo-
mib (myeloma), and Lenalidome (myeloma). CONCLUSIONS: Based on the retro-
spective analysis, it is clear that the biggest challenge for targeted-cancer therapies is 
affordability with only one of the targeted therapies receiving unconditional reim-
bursement. However, nearly all the other targeted therapies evaluated that offered >3 
months OS or PFS were recommended by NICE with a proviso to bring down the 
cost of treatment. Therefore, when companies develop their market access strategy, 
they should include a patient-access scheme in order to enter the UK market.
NI2
PATIENT ACCESS SCHEMES IN UK ARE DRIVEN BY HEALTH 
TECHNOLOGY ASSESMENT
Toumi M1, Jaroslawski S2
1University of Lyon, Lyon, France; 2Creativ Ceutical, Paris, Ile de France, France
OBJECTIVES: Achieving market access for new products has become complex for 
pharmaceutical companies. Faced with growing expenditure, health-care authorities 
accept or propose various schemes (risk sharing/payment for performance/commer-
cial): UK’s Department of Health coined a term Patient Access Scheme (PAS) and 
published speciﬁ c guidance for the industry. We performed an in-depth analysis of 
design of PASs in UK to revisit their typology and rationale. METHODS: We reviewed 
ofﬁ cial and grey literature on the Web sites of UK’s HTA Agency—NICE, the Depart-
ment of Health (DoH), the industry, and in the Internet. We searched for documents 
containing all synonimes of PAS and different scheme types. We selected PASs 
launched after 2006. RESULTS: We identiﬁ ed 13 PASs, all of which were designed/
implemented in consultation with NICE. Drug’s comparative effectiveness was central 
to the rationale behind the design of PASs. If effectiveness was acknowledged in the 
HTA, PAS was based on cost-containment (rituximab, erlotinib). If it was not recog-
nized, this was for one of the two reasons: (1) the uncertainity about the long-term 
effect of the drug, or (2) the value of ICER was questioned in the HTA. In case of 
(1), the PAS consisted in free provision of the drug by manufacturer after a predeﬁ ned 
period (lenalidomide, ranibizumab). In the case of (2), the PAS aimed at lowering the 
ICER either through cost containment (sunitinib, cetuximab, pemetrexed), through 
linking payment to outcomes (bortezomib, omalizumab), or by a mix of the two 
(certolizumab, ustekinumab). CONCLUSIONS: Formalized Health Technology 
Assessment is both a prerequisite and reason for implementing Patient Access Schemes 
in the UK. If the comparative effectiveness of a drug is acknowledged, the agreement 
is based on cost containment. On the other hand, if it is questioned, the PAS may 
have a form of a risk-sharing scheme and may be linking the payment to health 
outcomes (performance-based scheme).
NI3
NICE’S COST-EFFECTIVENESS THRESHOLD REVISITED: NEW 
EVIDENCE ON THE INFLUENCE OF COST-EFFECTIVENESS AND OTHER 
FACTORS ON NICE DECISIONS
Devlin N1, Dakin H2, Rice N3, Parkin D4, O’Neill P1
1Ofﬁ ce of Health Economics, London, UK; 2University of Oxford, Oxford, UK; 3University of 
York, York, UK; 4NHS South East Coast, Horley, Surrey, UK
OBJECTIVES: Since its establishment, NICE has become increasingly explicit about 
the way it uses evidence on cost-effectiveness in decision-making—and, more recently, 
about the other factors it considers. This, together with other ways in which decision-
making has evolved, suggests a number of testable hypotheses. We propose and 
empirically test alternative ways that NICE decision-making might be modeled, build-
ing on and extending Devlin and Parkin (2004) and Dakin et al. (2006). The large 
number of NICE decisions now observable facilitates the use of more sophisticated 
modeling techniques. METHODS: NICE’s decisions are characterized as binary 
choices: yes or no to a technology in a speciﬁ cally deﬁ ned patient group or indication. 
NICE Guidance often contains multiple such decisions. The probability of NICE 
recommending a technology is modeled as depending on evidence on effectiveness and 
cost-effectiveness; characteristics of the patients, disease, or treatment; and contextual 
factors. Data were obtained from HTAinSite (http://www.htainsite.com) on November 
2009. RESULTS: Initial results, drawing on data for 262 decisions, suggest cost-
effectiveness alone explains the vast majority of NICE’s decisions, correctly classifying 
85%, with high sensitivity and speciﬁ city. The estimated threshold, around £40k, is 
higher than NICE’s stated threshold (20k–£30k) but similar to that estimated by 
Devlin and Parkin (2004). Results across alternative model speciﬁ cations showed that 
almost none of the other variables exert a statistically signiﬁ cant effect on decisions, 
with two exceptions. First, technologies for the treatment of cancer have a signiﬁ cantly 
higher probability of being accepted, ceteris paribus, implying a willingness to pay an 
additional >£10k per QALY gained by cancer patients. Second, analysis of the subset 
of decisions made after NICE’s second “social value judgement” document suggest an 
increased probability of rejection. CONCLUSIONS: This is work in progress; further 
results will be available to report from additional data extraction and modeling.
NI4
DO PATIENT ACCESS SCHEMES RESULT IN AN ACCEPTABLE 
ADMINISTRATIVE BURDEN?
Haynes S, Costello S, Kusel J, Hamer N, Brooks-Rooney C
Costello Medical Consulting Ltd., Cambridge, UK
OBJECTIVES: In the UK, Patient Access Schemes (PAS) have become more common 
in submissions to the National Institute for Health and Clinical Excellence (NICE). 
The increase in PAS is a result of the essential role such schemes play in enhancing 
the availability of high-cost treatments to payers. In published appraisals, minimal 
emphasis has been placed upon the administrative burden of PAS, which is typically 
described as “acceptable.” The aim of this study was to assess the impact of admin-
istering PAS in the UK, using both primary research and existing literature to identify 
key administrative challenges. METHODS: A literature search was conducted using 
PubMed and Google Scholar. Freedom of information requests were sent to NICE for 
data on PAS administration. a pilot questionnaire was distributed to all 19 contacts 
listed on the directory of NHS Chief Pharmacists in Wales, to assess the real-life 
burden of PAS administration. RESULTS: Limited literature is available on the admin-
istration of PAS. However, the literature search uncovered evidence that the admin-
istrative impact of PAS is being recognized. The creation of the Patient Access Scheme 
Liaison Unit (PASLU) in October 2009 and the publication of the Pharmaceutical 
Price Regulation Scheme (PPRS) are two such developments, both of which are steps 
toward a system that more accurately reﬂ ects the needs of NHS administrators. The 
return rate for the questionnaire was low; however, responders showed dissatisfaction 
with multiple aspects of PAS management. Responders emphasized the need to address 
NHS requirements (both ﬁ nancial and temporal) in order to facilitate accurate PAS 
administration. CONCLUSIONS: Encouraging steps have been taken to recognize the 
burden of PAS on the NHS; however, further research is required to assess whether 
these recent developments are meaningful in everyday practice. Additional support for 
appropriate PAS implementation must also be provided if these important schemes are 
to continue effectively. 
PODIUM SESSION III: BIASES, METHODOLOGICAL CHALLENGES, AND 
SOLUTIONS
BI1
ANALYZING OVERALL SURVIVAL IN RANDOMIZED CONTROLLED 
TRIALS WITH CROSS-OVER
Jonsson L1, Sandin R2, Ekman M1, Ramsberg J1, Charbonneau C3, Huang X4, Jonsson B5, 
Weinstein MC6, Drummond M7
1i3 Innovus, Stockholm, Sweden; 2Pﬁ zer Oncology, Sollentuna, Stockholm, Sweden; 3Pﬁ zer, 
Inc, New York, NY, USA; 4Pﬁ zer Oncology, La Jolla, CA, USA; 5Stockholm School of 
Economics, Stockholm, Sweden; 6Harvard School of Public Health, Boston, MA, USA; 
7University of York, York, UK
BACKGROUND: Offering patients in oncology trials the opportunity to cross over 
to active treatment at disease progression is a commonly used strategy to address 
ethical issues associated with the use of placebo controls, but could lead to statistical 
challenges for the analysis of key end points such as overall survival. While an advan-
tage from the perspective of the treated patient enrolled in the trial, cross-over leads 
to loss of information and dilution of the comparative clinical efﬁ cacy and cost-
effectiveness results. OBJECTIVES: The purpose of the study is to compare alternative 
methods for analyzing overall survival data in the presence of cross-over, thus illustrat-
ing differences between methods, and providing guidance on choice of methodology. 
METHODS: Two promising methods for dealing with cross-over are inverse probabil-
ity of censoring weighting and the rank-preserving structural failure time model. The 
methods are compared with naïve censoring of data at cross-over and intention-to-
treat analysis ignoring cross-over using two recent examples of trials in oncology: the 
receptor tyrosine kinase inhibitor sunitinib in renal cell carcinoma (RCC) and in 
gastrointestinal stromal tumor (GIST). RESULTS: The analyses showed that for a trial 
with a low proportion of cross-over from placebo to active treatment (RCC), the 
choice of statistical method did not affect the results to a great extent; the range of 
relative mortality risk for active treatment versus control was narrow. With a high 
proportion of cross-over (GIST), the range of relative mortality risks was broader. 
CONCLUSIONS: Naïve censoring at cross-over can lead to bias and should be 
avoided. If cross-over occurs frequently, the inverse probability of censoring weighting 
method or the rank-preserving structural failure time model are recommended depend-
ing on the characteristics of cross over in the trial, trial size, and available data.
BI2
MULTIPLE COHORT MODELING OF LONG-DURATION 
INTERVENTIONS: QUESTIONING TIME HORIZONS AND 
AGGREGATION ACROSS COHORTS
O’Mahony J
Erasmus University Medical Center, Rotterdam, The Netherlands
BACKGROUND: Models are widely used in the cost-effectiveness analysis of health-
care interventions. Most models only simulate one patient cohort, but some use 
multiple cohorts. Advocates of multicohort modeling contend it better represents 
actual health-care implementation, especially where interventions are applied over 
speciﬁ c age ranges, as in cancer screening. When such an intervention is introduced, 
cohorts already older than the starting age only receive a partial intervention, possibly 
